Cardiovascular Therapeutic Drugs segmentation by application delineates the therapeutic intent of each product class and directly maps to revenue streams within the overall market. The largest share, Hypertension, accounts for roughly 35 % of global sales, reflecting the high prevalence of elevated blood pressure and the extensive formulary inclusion of ACE inhibitors, ARBs, and calcium‑channel blockers. Dyslipidemia follows with an estimated 25 % share, driven by statin‑centric lipid‑lowering regimens and growing demand for PCSK9 inhibitors. Arrhythmia therapies, comprising anti‑arrhythmic agents and catheter‑based solutions, contribute about 15 % of the market, a proportion sustained by aging demographics and increased detection of atrial fibrillation. Heart Failure treatments, including beta‑blockers, neprilysin inhibitors, and SGLT2 inhibitors, also represent 15 % of sales, underscoring the shift toward disease‑modifying therapies. Finally, Thrombosis management—encompassing antiplatelet and anticoagulant drugs—holds a 10 % share, reflecting the expanding use of direct oral anticoagulants in both acute and chronic settings. These application slices collectively define the strategic focus for R&D investment and pricing policy across the sector.
